Ligand Pharmaceuticals
LGND
204 hedge funds and large institutions have $1.12B invested in Ligand Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 79 increasing their positions, 67 reducing their positions, and 33 closing their positions.
52% more call options, than puts
Call options by funds: $3.97M | Put options by funds: $2.61M
18% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 67
3.13% more ownership
Funds ownership: 87.07% → 90.2% (+3.1%)
2% more capital invested
Capital invested by funds: $1.1B → $1.12B (+$22.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 212 → 204 (-8)
24% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 33
Top Buyers
| 1 |
Man Group
London,
United Kingdom
|
+$11M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$8.04M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$6.35M |
| 4 |
BlackRock
New York
|
+$5.06M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.61M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.25M |
| 2 |
Millennium Management
New York
|
-$3.09M |
| 3 |
Impax Asset Management Group
London,
United Kingdom
|
-$2.63M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$2.58M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.47M |
LGND Hedge Fund Activity: Q2 2023 in Review
204 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2023, worth a combined $1.12B — up 2% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of LGND and 25 opened new positions — a net loss of 8 holders — while 67 trimmed existing stakes and 79 added.
The largest buyer was Man Group, opening a new position worth an estimated $11M. The largest seller was Citadel Advisors, cutting an estimated $5.25M.
- 204 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2023, down from 212 in Q1 2023.
- Funds reported $1.12B of Ligand Pharmaceuticals stock for Q2 2023, up 2% quarter-over-quarter.
- 25 funds opened new Ligand Pharmaceuticals positions in Q2 2023 and 33 closed out, a net change of -8 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2023 was Man Group, an estimated $11M added.
- The largest Ligand Pharmaceuticals seller in Q2 2023 was Citadel Advisors, an estimated $5.25M sold.
Based on aggregated 13F filings for Q2 2023.